Literature DB >> 33077051

A comparison of patient treatment pathways among multidrug-resistant and drug-sensitive TB cases in Delhi, India: A cross-sectional study.

Nandini Sharma1, Anuj Bhatnagar2, Saurav Basu3, Ashwani Khanna4, K K Chopra5, Bratati Banerjee1, Neha Sharma1, Shivani Chandra6, Vishal Khanna7, Reema Arora8, Neeti Babbar9.   

Abstract

BACKGROUND: The delay in the diagnosis and treatment initiation of patients with MDR-TB worsens individual prognosis and increases the risk of disease transmission in the community. These delays have been attributed to delay in treatment-seeking by the patient and shifting to multiple healthcare facilities before being tested and diagnosed through India's National Tuberculosis Elimination Program (NTEP).
OBJECTIVE: to identify treatment pathways in patients with MDR-TB from the time of onset of symptoms and treatment seeking until diagnosis at a PMDT site and subsequent treatment initiation. We also compared these characteristics with those of patients with DS-TB.
METHODS: We recruited a total of 168 patients with MDR-TB and DS-TB each, in Delhi. Data were analyzed using IBM SPSS Version 25.
RESULTS: The mean (SD) patient delay for initial treatment-seeking was 20.9 (15.9) days in patients with MDR-TB, and 16.1 (17.1) days in patients with DS-TB (p < 0.001). The median time from visit to the first healthcare facility (HCF) until confirmation of MDR-TB diagnosis was 78.5 days, and until treatment initiation was 102.5 days. Among patients with DS-TB, the time interval from a visit to the first HCF until the initiation of ATT-DOTS was 61.5 days.. Patients diagnosed with DS-TB, whose first source of treatment was a private facility (n = 49), reported a significant delay in the initiation of ATT-DOTS (p < 0.001).
CONCLUSIONS: Despite the introduction of universal drug sensitivity testing in individuals having presumptive MDR-TB, a significant delay in the diagnosis and initiation of effective MDR-TB treatment persists as a major public health challenge in India.
Copyright © 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  India; MDR-TB; PMDT; Treatment pathways

Year:  2020        PMID: 33077051     DOI: 10.1016/j.ijtb.2020.07.020

Source DB:  PubMed          Journal:  Indian J Tuberc        ISSN: 0019-5707


  1 in total

1.  Expanding the Tuberculosis Cascade of Care to Treat Undiagnosed and Subclinical Tuberculosis in High-Burden Settings.

Authors:  Max O'Donnell; Barun Mathema
Journal:  Am J Respir Crit Care Med       Date:  2022-01-15       Impact factor: 21.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.